1. Home
  2. Directory
  3. Connecticut
  4. New Haven
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1477583540

DR. GERALDINE M FABREGAS MD
Prescription History 1477583540
Internal Medicine - Geriatric Medicine in New Haven, CT


Quality Rating: 93.27 out of 100 score

NPI Status: Active since July 04, 2006

Contact Information

280 ALDEN AVE
NEW HAVEN, CT
ZIP 06515
Phone: (203) 387-7719
Fax: (203) 397-5152

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. GERALDINE M FABREGAS MD, an active Geriatric Medicine specialist practicing in New Haven, CT. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 529 documented patient claims. Among these therapy options, the most frequently utilized medication is Donepezil Hcl, which accounts for 121 claims alone.

Medication Index

Donepezil Hcl

Generic Formulation: Donepezil HclSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 121
30-Day Fills 284.4
Days Supply 8,481
CT State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills86.5
Peer Average Days Supply2,503
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 137.3% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,189.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.09

State Avg Cost Per Claim

$15.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Donepezil is used to treat confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to function. This medication is an enzyme blocker that works by restoring the balance of natural substances (neurotransmitters) in the brain.

Fluoxetine Hcl

Generic Formulation: Fluoxetine HclSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 24
30-Day Fills 28.0
Days Supply 780
CT State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills66.7
Peer Average Days Supply1,970
Conservative Utilization

This provider writes prescriptions for this formulation 31.4% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $250.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.43

State Avg Cost Per Claim

$17.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.

Therapeutic Applications

This long-acting form of fluoxetine is used to treat depression in people who have been successfully treated with the form of fluoxetine that is taken daily. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). SSRIs work by helping to restore the balance of certain natural substances in the brain (neurotransmitters such as serotonin). Fluoxetine may decrease anxiety, improve your mood, sleep, appetite, and energy level and may help restore your interest in daily living.

Memantine Hcl

Generic Formulation: Memantine HclSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 89
30-Day Fills 236.4
Days Supply 7,060
CT State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills70.9
Peer Average Days Supply2,027
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 89.4% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,102.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$79.81

State Avg Cost Per Claim

$59.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Memantine is used to treat moderate to severe confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by blocking the action of a certain natural substance in the brain (glutamate) that is believed to be linked to symptoms of Alzheimer's disease.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 25
30-Day Fills 50.0
Days Supply 1,500
CT State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills71.1
Peer Average Days Supply2,021
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.0% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,112.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.50

State Avg Cost Per Claim

$27.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Quetiapine Fumarate

Generic Formulation: Quetiapine FumarateSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 36
30-Day Fills 56.5
Days Supply 1,674
CT State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills75.5
Peer Average Days Supply2,132
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $805.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.38

State Avg Cost Per Claim

$35.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

Therapeutic Applications

This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. It may also improve your mood, sleep, appetite, and energy level. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur.

Rivastigmine

Generic Formulation: RivastigmineSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 70
30-Day Fills 101.0
Days Supply 3,030
CT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply940
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 204.3% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,095.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$229.93

State Avg Cost Per Claim

$307.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

Therapeutic Applications

Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

Rivastigmine

Generic Formulation: Rivastigmine TartrateSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 32
30-Day Fills 64.0
Days Supply 1,914
CT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply940
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 39.1% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,322.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$135.08

State Avg Cost Per Claim

$307.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

Therapeutic Applications

Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

Sertraline Hcl

Generic Formulation: Sertraline HclSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 77
30-Day Fills 138.8
Days Supply 4,056
CT State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills104.3
Peer Average Days Supply3,057
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.5% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $571.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.42

State Avg Cost Per Claim

$12.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Sertraline is used to treat depression, panic attacks, obsessive compulsive disorder, post-traumatic stress disorder, social anxiety disorder (social phobia), and a severe form of premenstrual syndrome (premenstrual dysphoric disorder). This medication may improve your mood, sleep, appetite, and energy level and may help restore your interest in daily living. It may decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. It may also reduce the urge to perform repeated tasks (compulsions such as hand-washing, counting, and checking) that interfere with daily living. Sertraline is known as a selective serotonin reuptake inhibitor (SSRI). It works by helping to restore the balance of a certain natural substance (serotonin) in the brain.

Trazodone Hcl

Generic Formulation: Trazodone HclSpecialty: Geriatric Medicine
Provider Metrics Summary
Total Claims 55
30-Day Fills 107.1
Days Supply 3,145
CT State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills109.1
Peer Average Days Supply3,071
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $640.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.64

State Avg Cost Per Claim

$13.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat depression. It may help to improve your mood, appetite, and energy level as well as decrease anxiety and insomnia related to depression. Trazodone works by helping to restore the balance of a certain natural chemical (serotonin) in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. GERALDINE M FABREGAS MD provides transparency into local medical care patterns within New Haven, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Geriatric Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.